Monitor Detect
Intervene
Actionable insights based on post-operative tissue healing data
Exero’s xBar system empowers health care providers with high-quality, actionable post-operative data directly from the surgical site that can save lives, improve patient prognosis, and reduce cost of care.
Complications after GI Sugery
Complications after gastrointestinal surgery, such as anastomotic leaks, can have profound consequences for patients, and can lead to increased morbidity, mortality, and prolonged hospital stays.
Early diagnosis and management of complications are critical to minimizing adverse consequences for the patient. However, the diagnosis of leaks still largely relies on clinical presentation of symptoms and imaging studies, and in many cases, leaks do not present until 8 or more days after surgery.
5 MILLION Gasrointestinal sugeries annually
6-10%
Post-operative complication rate
8 Days
Average time to detection
20-40%
Mortality rate if complications arise
$7 Billion
Overall healthcare burden
Electrode sensors embedded in a standard surgical drain and placed near the anastomosis site.
The electrodes are connected to a small electronic device outside the patient’s body that records and relays data.
Data is analyzes to indicate the risk of anastomotic leaks based on the status of tissue healing or damage.
The xBar System
Early and accurate, non-invasive, detection of leaks with the xBar system may allow for earlier intervention, minimizing major complications and their associated morbidity, mortality, and costs.
The xBar System is limited by U.S. law to investigational use and is not approved for sale or distribution in the US.
Press
Post-surgical tissue monitoring technology identified anastomotic leaks over three days earlier than standard clinical practice, with 100% sensitivity and 88% specificity
Enrollment milestone advances Exero Medical toward planned FDA submission of its breakthrough designated xBar system for early anastomotic leak detection.
Exero Medical, a US and Israel based company focused on early detection of post-operative complications using tissue healing data, has secured up to $12.7M in funding to complete its FDA pivotal trial and launch its breakthrough-designated xBar system in the United States. The round includes $10M in upfront funding and additional milestone-based warrants, as well as $2.7M in non-dilutive grants.
Proven Performance. Measurable Impact
Learn more about the xBar system today.